UY27862A1 - Nuevos ligandos del receptor de glucocorticoides - Google Patents
Nuevos ligandos del receptor de glucocorticoidesInfo
- Publication number
- UY27862A1 UY27862A1 UY27862A UY27862A UY27862A1 UY 27862 A1 UY27862 A1 UY 27862A1 UY 27862 A UY27862 A UY 27862A UY 27862 A UY27862 A UY 27862A UY 27862 A1 UY27862 A1 UY 27862A1
- Authority
- UY
- Uruguay
- Prior art keywords
- compounds
- new
- ligands
- receiver
- methods
- Prior art date
Links
- 239000003862 glucocorticoid Substances 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 230000018406 regulation of metabolic process Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
- C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17475002A | 2002-06-19 | 2002-06-19 | |
| US10/460,491 US7141559B2 (en) | 2002-06-19 | 2003-06-12 | Glucocorticoid receptor ligands for the treatment of metabolic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY27862A1 true UY27862A1 (es) | 2004-04-30 |
Family
ID=30002639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY27862A UY27862A1 (es) | 2002-06-19 | 2003-06-20 | Nuevos ligandos del receptor de glucocorticoides |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1551860B1 (enExample) |
| JP (1) | JP4611019B2 (enExample) |
| KR (1) | KR101100826B1 (enExample) |
| CN (1) | CN100348609C (enExample) |
| AR (1) | AR040278A1 (enExample) |
| AT (1) | ATE346082T1 (enExample) |
| AU (1) | AU2003243622B9 (enExample) |
| CA (1) | CA2488535C (enExample) |
| CY (1) | CY1105982T1 (enExample) |
| DE (1) | DE60309909T2 (enExample) |
| DK (1) | DK1551860T3 (enExample) |
| ES (1) | ES2278195T3 (enExample) |
| PT (1) | PT1551860E (enExample) |
| TW (1) | TWI285646B (enExample) |
| UY (1) | UY27862A1 (enExample) |
| WO (1) | WO2004000869A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7605264B2 (en) | 2004-01-16 | 2009-10-20 | Bristol-Myers Squibb Company | Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7253283B2 (en) | 2004-01-16 | 2007-08-07 | Bristol-Myers Squibb Company | Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7326728B2 (en) | 2004-01-16 | 2008-02-05 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κβ activity and use thereof |
| US7569689B2 (en) | 2004-01-16 | 2009-08-04 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7625921B2 (en) | 2004-01-16 | 2009-12-01 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7273881B2 (en) | 2004-01-16 | 2007-09-25 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7642273B2 (en) | 2005-01-13 | 2010-01-05 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7411071B2 (en) | 2005-01-13 | 2008-08-12 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7361654B2 (en) | 2005-01-13 | 2008-04-22 | Bristol-Myers Squibb Co. | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7317024B2 (en) | 2005-01-13 | 2008-01-08 | Bristol-Myers Squibb Co. | Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| GB0514302D0 (en) * | 2005-07-12 | 2005-08-17 | Karobio Ab | Improved crystalline material |
| US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| WO2011058193A1 (en) | 2009-11-16 | 2011-05-19 | Mellitech | [1,5]-diazocin derivatives |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| CA2826649C (en) | 2011-02-25 | 2016-07-26 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| PT2758060T (pt) * | 2011-09-19 | 2018-01-24 | ETH Zürich | Moduladores de ror gama para o tratamento de complicações de diabetes ii |
| US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| JP2016516004A (ja) | 2013-02-22 | 2016-06-02 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗糖尿病二環式化合物 |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| EP2781217A1 (en) * | 2013-03-18 | 2014-09-24 | ETH Zurich | ROR gamma modulators |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| CN105693808B (zh) * | 2015-11-05 | 2018-03-16 | 华润紫竹药业有限公司 | 一种醋酸乌立妥原料药杂质及其制备方法和作为标准品的用途 |
| FR3055627A1 (fr) * | 2016-09-08 | 2018-03-09 | Laboratoire Hra-Pharma | Methode de preparation du compose cdb-3877 |
| FR3055626B1 (fr) * | 2016-09-08 | 2018-10-12 | Hra Pharma Lab | Procede de synthese d'un compose steroide comprenant un substituant n-methylaniline en position 11 |
| WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| CN114230627B (zh) * | 2021-12-31 | 2023-09-15 | 湖南新合新生物医药有限公司 | 一种倍他米松环氧水解物中间体的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3930696A1 (de) * | 1989-09-14 | 1991-03-28 | Hoechst Ag | Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel |
| DE4000397A1 (de) * | 1990-01-09 | 1991-07-11 | Hoechst Ag | Lipidselektive antioxidantien sowie deren herstellung und verwendung |
| US5250524A (en) * | 1990-12-06 | 1993-10-05 | Hoechst Aktiengesellschaft | Bile acid derivatives, process for their preparation and use of these compounds as pharmaceuticals |
| GB9907048D0 (en) * | 1999-03-27 | 1999-05-19 | Karobio Ab | Novel glucocorticoid receptor ligands for the treatment of meta bolic disorders |
-
2003
- 2003-06-17 PT PT03761096T patent/PT1551860E/pt unknown
- 2003-06-17 CA CA2488535A patent/CA2488535C/en not_active Expired - Fee Related
- 2003-06-17 EP EP03761096A patent/EP1551860B1/en not_active Expired - Lifetime
- 2003-06-17 CN CNB03814137XA patent/CN100348609C/zh not_active Expired - Fee Related
- 2003-06-17 DE DE60309909T patent/DE60309909T2/de not_active Expired - Lifetime
- 2003-06-17 JP JP2004515868A patent/JP4611019B2/ja not_active Expired - Fee Related
- 2003-06-17 ES ES03761096T patent/ES2278195T3/es not_active Expired - Lifetime
- 2003-06-17 AT AT03761096T patent/ATE346082T1/de active
- 2003-06-17 WO PCT/US2003/019157 patent/WO2004000869A1/en not_active Ceased
- 2003-06-17 KR KR1020047020680A patent/KR101100826B1/ko not_active Expired - Fee Related
- 2003-06-17 AU AU2003243622A patent/AU2003243622B9/en not_active Ceased
- 2003-06-17 DK DK03761096T patent/DK1551860T3/da active
- 2003-06-18 TW TW092116530A patent/TWI285646B/zh not_active IP Right Cessation
- 2003-06-19 AR ARP030102178A patent/AR040278A1/es unknown
- 2003-06-20 UY UY27862A patent/UY27862A1/es not_active Application Discontinuation
-
2007
- 2007-02-02 CY CY20071100150T patent/CY1105982T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003243622A2 (en) | 2004-01-06 |
| CA2488535C (en) | 2012-02-07 |
| AU2003243622A1 (en) | 2004-01-06 |
| DE60309909D1 (de) | 2007-01-04 |
| CN100348609C (zh) | 2007-11-14 |
| DK1551860T3 (da) | 2007-04-02 |
| DE60309909T2 (de) | 2007-06-21 |
| ATE346082T1 (de) | 2006-12-15 |
| EP1551860A1 (en) | 2005-07-13 |
| CY1105982T1 (el) | 2011-04-06 |
| WO2004000869A1 (en) | 2003-12-31 |
| CN1662549A (zh) | 2005-08-31 |
| AU2003243622B2 (en) | 2009-05-28 |
| KR101100826B1 (ko) | 2012-01-02 |
| KR20050016588A (ko) | 2005-02-21 |
| EP1551860B1 (en) | 2006-11-22 |
| AR040278A1 (es) | 2005-03-23 |
| JP2005533807A (ja) | 2005-11-10 |
| TW200410983A (en) | 2004-07-01 |
| JP4611019B2 (ja) | 2011-01-12 |
| TWI285646B (en) | 2007-08-21 |
| PT1551860E (pt) | 2007-02-28 |
| ES2278195T3 (es) | 2007-08-01 |
| AU2003243622B9 (en) | 2009-07-16 |
| CA2488535A1 (en) | 2003-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1105982T1 (el) | Συνδετες υποδοχεων γλυκοκορτικοειδων για την θepαπεια των μεταβολικων διαταραχων | |
| DK1725660T3 (da) | Ekspressionskassetter med multiple promotorer til samtidig afgivelse af RNAi-midler | |
| ZA200701656B (en) | Humanized anti-cment antagonists | |
| UY28276A1 (es) | Ligandos de receptores de cannabinoides y sus usos | |
| CL2009000090A1 (es) | Anticuerpo que se une al receptor de tirosina quinasa b (trkb); composicion que comprende el anticuerpo; metodo para reducir los niveles de glucosa en la sangre y/o el peso corporal en un individuo. | |
| BRPI0508629A (pt) | trilho lateral para uso com um suporte para paciente | |
| NO20051941L (no) | Kombinasjonskjemoterapisammensetninger og fremgangsmater. | |
| ATE472551T1 (de) | Tocopherolmodifizierte therapeutische arzneimittelverbindung | |
| ECSP088508A (es) | Antagonistas de neuropilina | |
| GT200600046A (es) | Terapia de combinacion | |
| ECSP077336A (es) | Control de parásitos en animales mediante el uso de nuevos derivados de trifluorometansulfonanilida oxima éter | |
| MX341370B (es) | Antagonistas anti - beta7 humanizados y usos para los mismos. | |
| DE602004012083D1 (de) | Substituirte benzosulfonamide als potenzierungsmittel von glutamatrezeptoren | |
| NO20063422L (no) | Spirosyklisk sykloheksanderivater med affinitet for ORL1-reseptoren | |
| ATE473744T1 (de) | Modifizierte pyrimidin-glucocorticoid-rezeptor- modulatoren | |
| CO6290752A2 (es) | Antagonistas n,n-disustituidos de aminoalquilbifenilo de receptores d2 de prostaglandina | |
| BRPI0816954A2 (pt) | Composição de café, e, métodos para preparar uma composição, e para preparar uma bebida de café de três camadas | |
| NO20072004L (no) | Substituerte kromanderivater, medikamenter og anvendelse i terapi | |
| MX2010001574A (es) | Ligandos del receptor cannabinoide. | |
| HN2004000109A (es) | Nueva difenilazetidinona con propiedades fisiologicas mejoradas, procedimiento para su preparacion, medicamentos que comprenden este compuesto y su uso | |
| TW200531679A (en) | Methods of modulating cytokine activity; related reagents | |
| DE60125417D1 (de) | Verminderung der nebenwirkungen der chemotherapie in krebspatienten | |
| SV2008002856A (es) | 2-amino-7, 8-dihidro-6h-pirido [4,3-d] pirimidina-5-onas | |
| WO2006029220A3 (en) | Combination therapy with anti-ctla4 and anti-4-1bb antibodies | |
| UY26473A1 (es) | Compuestos activos en el receptor de glucocorticoide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20150223 |